New Relic (NEWR) Given Outperform Rating at Wedbush
From:www.tickerreport.com
Wedbush reissued their outperform rating on shares of New Relic (NYSE:NEWR) in a research note released on Wednesday morning, Marketbeat Ratings reports. They currently have a $116.00 price target on the software maker’s stock, down from their...Read More>>>
Insider Buying: Special Opportunities Fund, Inc. (SPE) Insider Purchases $14,470.00 in Stock
From:www.tickerreport.com
Special Opportunities Fund, Inc. (NYSE:SPE) insider Gerald Hellerman bought 1,000 shares of the firm’s stock in a transaction on Thursday, October 11th. The stock was purchased at an average cost of $14.47 per share, with a total value of $14,4...Read More>>>
Ferrari (RACE) Raised to Hold at Societe Generale
From:www.tickerreport.com
Societe Generale upgraded shares of Ferrari (NYSE:RACE) from a sell rating to a hold rating in a research report released on Wednesday morning, Marketbeat reports. Societe Generale currently has $130.00 target price on the stock, up from their previo...Read More>>>
Akoustis Technologies (AKTS) Coverage Initiated at Piper Jaffray Companies
From:www.tickerreport.com
Piper Jaffray Companies started coverage on shares of Akoustis Technologies (NASDAQ:AKTS) in a report published on Wednesday, The Fly reports. The brokerage issued a buy rating and a $10.00 target price on the technology company’s stock.
A numb...Read More>>>
IDEX Co. (IEX) Declares Quarterly Dividend of $0.43
From:www.tickerreport.com
IDEX Co. (NYSE:IEX) announced a quarterly dividend on Thursday, September 13th, RTT News reports. Investors of record on Tuesday, October 16th will be paid a dividend of 0.43 per share by the industrial products company on Wednesday, October 31st. Th...Read More>>>
We are a clinical-stage immuno-oncology company and a leader in the field of
neoantigen-targeted therapies, dedicated to transforming the treatment of cancer
by directing the immune system towards neoantigens. Genetic mutations, which are
a hallmark of cancer, can result in specific immune targets called neoantigens.
The presence of neoantigens in cancer cells and their absence in normal cells
makes them compelling, untapped targets for cancer therapy. By directing the
immune system towards these targets, we believe our neoantigen-targeted
therapies will offer a new level of patient and tumor specificity in the field
of cancer immunotherapy that will drive a strong risk-benefit profile to
dramatically improve patient outcomes.
Our ambition is to lead a paradigm shift in the treatment of cancer patients
towards an era of truly personal immuno-oncology therapies.
We are an innovative and fast growing “new e-commerce” platform that
provides buyers with value-for-money merchandise and fun and interactive
shopping experiences. Our Pinduoduo mobile platform offers a comprehensive
selection of attractively priced merchandise, featuring a dynamic social
shopping experience that leverages social networks as an effective and efficient
tool for buyer acquisition and engagement. As a result of our innovative
business model, we have been able to quickly expand our buyer base and establish
our brand recognition and market position. We are one of the leading Chinese
e-commerce players in terms of GMV and the number of total orders. Our GMV in
2017 and the twelve-month period ended June 30, 2018 was RMB141.2 billion and
RMB262.1 billion (US$41.8 billion), respectively. In 2017 and the twelve-month
period ended June 30, 2018, the number of total orders placed on our Pinduoduo
mobile platform reached 4.3 billion and 7.5 billion, respectively.
We are a leading partnership of independent, fiduciary wealth management
firms operating in the highly fragmented RIA industry, with a footprint of over
50 partner firms across the country. We have achieved this market leadership by
positioning ourselves as the partner of choice for many firms in an industry
where a number of secular trends are driving RIA consolidation. Our partner
firms primarily service high net worth individuals and families by providing
highly differentiated and comprehensive wealth management services. Our partner
firms benefit from our intellectual and financial resources, operating in a
scaled business model with aligned interests, while retaining their
entrepreneurial culture and independence.
We are an innovative biopharmaceutical company developing a novel and
proprietary class of biologic drugs for the selective modulation of the human
immune system to treat a broad range of cancers and autoimmune disorders. We
believe our innovative CUE Biologics(TM) platform approach to selectively modulate
disease relevant T cells, provides a transformative solution to the challenges
facing prevailing immunotherapeutics. By directly engaging and modulating
disease relevant T cells in the patient’s body via an injectable drug, we
believe our biologic drug candidates will be able to realize the true potential
of immune modulation. Through our proprietary CUE Biologics(TM) platform, we
believe we are uniquely positioned to become a prominent and leading player in
immunotherapy, immuno-oncology, and autoimmune disease.
To analyze our business performance, determine financial forecasts and help
develop long-term strategic plans, we review the following key business metric:
As of As of
December 31, June 30,
(in thousands) 2016 2017 2017 2018
Paying users 575 606 598 616
Paying users
We define a paying user as an individual customer of our survey platform or
form-based application, a seat within a SurveyMonkey Enterprise deployment or a
subscription to one of our purpose-built solutions. One person would count as
multiple paying users if the person had more than one paid license at the end of
the period. For example, if an individual paying user also had a designated seat
in a SurveyMonkey Enterprise deployment, we would count that person as two
paying users.
